CoChat

Glucose sensor-augmented continuous subcutaneous insulin infusion in patients with diabetic gastroparesis: An open-label pilot prospective study

Open access

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

Erratic blood glucose levels can be a cause and consequence of delayed gastric emptying in patients with diabetes. It is unknown if better glycemic control increases risks of hypoglycemia or improves hemoglobin A1c levels and gastrointestinal symptoms in diabetic gastroparesis. This study investigated the safety and potential efficacy of continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) in poorly controlled diabetes with gastroparesis. Forty-five type 1 or 2 patients with diabetes and gastroparesis and hemoglobin A1c >8% from the NIDDK Gastroparesis Consortium enrolled in a 24 week open-label pilot prospective study of CSII plus CGM. The primary safety outcome was combined numbers of mild, moderate, and severe hypoglycemic events at screening and 24 weeks treatment. Secondary outcomes included glycemic excursions on CGM, hemoglobin A1c, gastroparesis symptoms, quality-of-life, and liquid meal tolerance. Combined mild, moderate, and severe hypoglycemic events occurred similarly during the screening/run-in (1.9/week) versus treatment (2.2/week) phases with a relative risk of 1.18 (95% CI 0.85-1.64, P = 0.33). CGM time in hypoglycemia (<70 mg/dL) decreased from 3.9% to 1.8% (P<0.0001), time in euglycemia (70-180 mg/dL) increased from 44.0% to 52.0% (P = 0.02), time in severe hyperglycemia (>300 mg/dL) decreased from 14.2% to 7.0% (P = 0.005), and hemoglobin A1c decreased from 9.4±1.4% to 8.3±1.3% (P = 0.001) on CSII plus CGM. Symptom scores decreased from 29.3±7.1 to 21.9±10.2 with lower nausea/vomiting, fullness/early satiety, and bloating/distention scores (P≤0.001). Quality-of-life scores improved from 2.4±1.1 to 3.1±1.1 (P<0.0001) and volumes of liquid nutrient meals tolerated increased from 420±258 to 487±312 mL (P = 0.05) at 24 weeks. In conclusion, CSII plus CGM appeared to be safe with minimal risks of hypoglycemic events and associated improvements in glycemic control, gastroparesis symptoms, quality-of-life, and meal tolerance in patients with poorly controlled diabetes and gastroparesis. This study supports the safety, feasibility, and potential benefits of improving glycemic control in diabetic gastroparesis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0194759

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Flowchart for the GLUMIT-DG study. This figure shows the Flowchart for patient recruitment for the GLUMIT-DG study, which follows a non-randomized trial design. A TREND checklist accompanies this Flowchart as the S1 File in the Supplemental Information section.
Fig 1 Flowchart for the GLUMIT-DG study. This figure shows the Flowchart for patient recruitment for the GLUMIT-DG study, which follows a non-randomized trial design. A TREND checklist accompanies this Flowchart as the S1 File in the Supplemental Information section.CC0 · PubMed Central
Fig 2 Study design for GLUMIT-DG. The study design is shown. After an initial screening phase (up to 3 visits over up to 8 weeks), a run-in phase (up to 4 visits over up to 8 weeks) was conducted. The formal treatment phase consisted of 6 study visits over 24 weeks when CSII and CGM were used together to optimize glycemic control.
Fig 2 Study design for GLUMIT-DG. The study design is shown. After an initial screening phase (up to 3 visits over up to 8 weeks), a run-in phase (up to 4 visits over up to 8 weeks) was conducted. The formal treatment phase consisted of 6 study visits over 24 weeks when CSII and CGM were used together to optimize glycemic control.CC0 · PubMed Central
Fig 3 Effects of CSII plus CGM on glycemic parameters are shown. Treatment elicited significant reductions in hemoglobin A1c at 12 and 24 weeks of treatment compared to screening values (A). CGM readings revealed reductions in time in both hypo- and hyperglycemia with treatment at 24 weeks (blue) compared to the screening phase (orange) (B).
Fig 3 Effects of CSII plus CGM on glycemic parameters are shown. Treatment elicited significant reductions in hemoglobin A1c at 12 and 24 weeks of treatment compared to screening values (A). CGM readings revealed reductions in time in both hypo- and hyperglycemia with treatment at 24 weeks (blue) compared to the screening phase (orange) (B).CC0 · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 56

Metadata

Authors
Calles-Escandón, J., Koch, K. L., Hasler, W. L., Van Natta, M. L., Pasricha, P. J., Tonascia, J., Parkman, H. P., Hamilton, F., Herman, W. H., Basina, M., Buckingham, B., Earle, K., Kirkeby, K., Hairston, K., Bright, T., Rothberg, A. E., Kraftson, A. T., Siraj, E. S., Subauste, A., Lee, L. A., Abell, T. L., McCallum, R. W., Sarosiek, I., Nguyen, L., Fass, R., Snape, W. J., Vaughn, I. A., Miriel, L. A., Farrugia, G., & the NIDDK Gastroparesis Clinical Research Consortium (GpCRC)
Affiliations
  • MetroHealth (US)
  • Wake Forest University (US)
  • University of Michigan (US)
  • Johns Hopkins University (US)
  • Temple University (US)
  • National Institute of Diabetes and Digestive and Kidney Diseases (US)
  • Stanford Medicine (US)
  • California Pacific Medical Center (US)
  • Texas Tech University (US)
  • University of Mississippi Medical Center (US)
  • University of Louisville (US)
  • Mayo Clinic (US)
Corresponding author
Hasler, William L.
Venue
PLOS ONE
Published
2018-04-13
Volume
13
Issue
4
Pages
e0194759
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2805766648
Cited by
55
References
37
Citations by year
2026: 8 · 2025: 7 · 2024: 6 · 2023: 6 · 2022: 7 · 2021: 3 · 2020: 7 · 2019: 7 · 2018: 4
FWCI
4.17
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, public-domain)
  • Europe PMC (PubMed Central) (publishedVersion, public-domain)
  • PubMed Central (publishedVersion, public-domain)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
NIDDK (U01DK073983, U01DK073985, U01DK073975, U01DK074035, U01DK074007, U01DK073974, U01DK074008)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
diabetic gastroparesis, insulin pump therapy, continuous glucose monitoring, hypoglycemia, glycemic control, HbA1c, glycemic excursions, quality of life, type 1 diabetes, type 2 diabetes, gastric emptying, insulin dose
MeSH terms
Adolescent, Adult, Aged, Blood Glucose, Female, Humans, Insulin, Male, Middle Aged, Pilot Projects, Quality of Life, Treatment Outcome, Gastroparesis, Diabetes Complications, Infusions, Subcutaneous, Young Adult, Symptom Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucose sensor-augmented continuous subcutaneous insulin infusion in patients with diabetic gastroparesis: An open-label pilot prospective study. https://app.cochat.ai/papers/10.1371/journal.pone.0194759
The paper
Calles-Escandón, J., Koch, K. L., Hasler, W. L., Van Natta, M. L., Pasricha, P. J., Tonascia, J., Parkman, H. P., Hamilton, F., Herman, W. H., Basina, M., Buckingham, B., Earle, K., Kirkeby, K., Hairston, K., Bright, T., Rothberg, A. E., Kraftson, A. T., Siraj, E. S., Subauste, A., . . . the NIDDK Gastroparesis Clinical Research Consortium (GpCRC). (2018). Glucose sensor-augmented continuous subcutaneous insulin infusion in patients with diabetic gastroparesis: An open-label pilot prospective study. PLOS ONE. https://doi.org/10.1371/journal.pone.0194759

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.